Patents by Inventor Archie A. Silver
Archie A. Silver has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10188613Abstract: A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition.Type: GrantFiled: May 3, 2018Date of Patent: January 29, 2019Assignee: UNIVERSITY OF SOUTH FLORIDAInventors: Douglas Shytle, Paul R. Sanberg, Mary Newman, Archie A. Silver
-
Publication number: 20180250244Abstract: A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition.Type: ApplicationFiled: May 3, 2018Publication date: September 6, 2018Inventors: DOUGLAS SHYTLE, PAUL R. SANBERG, MARY NEWMAN, ARCHIE A. SILVER
-
Patent number: 9593070Abstract: A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition.Type: GrantFiled: March 12, 2014Date of Patent: March 14, 2017Assignee: UNIVERSITY OF SOUTH FLORIDAInventors: Douglas Shytle, Paul Sanberg, Mary Newman, Archie A. Silver
-
Publication number: 20140194525Abstract: A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition.Type: ApplicationFiled: March 12, 2014Publication date: July 10, 2014Applicant: Targacept, Inc.Inventors: Douglas Shytle, Paul Sanberg, Mary Newman, Archie A. Silver
-
Patent number: 8026283Abstract: A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition.Type: GrantFiled: January 4, 2010Date of Patent: September 27, 2011Assignee: University of South FloridaInventors: Douglas Shytle, Paul Sanberg, Mary Newman, Archie A. Silver
-
Publication number: 20110028565Abstract: A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition.Type: ApplicationFiled: September 21, 2010Publication date: February 3, 2011Applicant: University of South FloridaInventors: Douglas Shytle, Paul Sanberg, Mary Newman, Archie A. Silver
-
Publication number: 20100286282Abstract: A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition.Type: ApplicationFiled: January 4, 2010Publication date: November 11, 2010Applicant: Targacept, Inc.Inventors: Douglas Shytle, Paul Sanberg, Mary Newman, Archie A. Silver
-
Publication number: 20060276551Abstract: A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition.Type: ApplicationFiled: April 5, 2006Publication date: December 7, 2006Inventors: Douglas Shytle, Paul Sanberg, Mary Newman, Archie Silver
-
Patent number: 7101916Abstract: A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition.Type: GrantFiled: May 19, 2003Date of Patent: September 5, 2006Assignee: University of South FloridaInventors: Douglas Shytle, Paul Sanberg, Mary Newman, Archie A. Silver
-
Patent number: 6979698Abstract: The treatment of learning, memory, and age-related memory disorders includes administration of a nicotine antagonist. The preferred nicotine antagonists are mecamylamine, a mecamylamine analog, or a mecamylamine stereoisomer. The effective amount of the nicotine antagonist is 0.005–1.00 mg/kg/day. Alternatively, the method utilizes a partial nicotine agonist.Type: GrantFiled: March 15, 2000Date of Patent: December 27, 2005Assignee: Targacept, Inc.Inventors: Paul R. Sandberg, Roland D. Shytle, Archie A. Silver
-
Patent number: 6734215Abstract: Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition. The medical conditions include substance addiction (involving nicotine, cocaine, alcohol, amphetamine, opiate, other psychostimulant and a combination thereof), Tourette's Syndrome, and neuropsychiatric disorders (such as bipolar disorder, depression, an anxiety disorder, schizophrenia, a seizure disorder, Parkinson's disease and attention deficit hyperactivity disorder).Type: GrantFiled: June 15, 2001Date of Patent: May 11, 2004Assignee: University of South FloridaInventors: Douglas Shytle, Paul Sanberg, Mary Newman, Archie A. Silver
-
Publication number: 20040044083Abstract: A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition.Type: ApplicationFiled: September 23, 2003Publication date: March 4, 2004Applicant: University of South FloridaInventors: Douglas Shytle, Paul Sanberg, Mary Newman, Archie A. Silver
-
Publication number: 20020016370Abstract: A pharmaceutical composition includes a therapeutically effective amount of exo-R-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-S-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-R-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-S-mecamylamine, said amount being sufficient to ameliorate the medical condition.Type: ApplicationFiled: June 15, 2001Publication date: February 7, 2002Inventors: Douglas Shytle, Paul Sanberg, Mary Newman, Archie A. Silver
-
Publication number: 20020016371Abstract: A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition.Type: ApplicationFiled: June 15, 2001Publication date: February 7, 2002Inventors: Douglas Shytle, Paul Sanberg, Mary Newman, Archie A. Silver
-
Patent number: 6034079Abstract: Nicotine-responsive neuropsychiatric disorders can be treated by administering a nicotine antagonist, particularly mecamylamine. Combination therapy of mecamylamine with a neuroleptic drug also is disclosed. The neuropsychiatric disorders include Tourette's syndrome, schizophrenia, depression, bipolar disorder, tremors, attention deficit hyperactivity disorder, obsessive-compulsive disorder, hemidystonia, rage outbursts and tardive dyskinesia.Type: GrantFiled: November 23, 1998Date of Patent: March 7, 2000Assignee: University of South FloridaInventors: Paul R. Sanberg, Roland D. Shytle, Archie A. Silver